



中文标题

检索

跨刊检索

江香薷的极性成分研究 II

投稿时间: 2011-01-14 责任编辑: 丁广治 [点此下载全文](#)

引用本文: 沈娟娟,张东明,刘华,罗永明.江香薷的极性成分研究II[J].中国中药杂志,2011,36(13):1779.

DOI: 10.4268/cjcm20111319

摘要点击次数: 1022

全文下载次数: 270

广告合作



作者中文名	作者英文名	单位中文名	单位英文名	E-Mail
沈娟娟	SHEN Juanjuan	江西中医学院 药学院, 江西 南昌 330004	Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China	
张东明	ZHANG Dongming	中国医学科学院 中国协和医科大学 药物研究所, 北京 100050	Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China	
刘华	LIU Hua	江西中医学院 药学院, 江西 南昌 330004	Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China	winner616@163.com
罗永明	LUO Yongming	江西中医学院 药学院, 江西 南昌 330004	Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China	

基金项目:江西省卫生厅重点项目(2008ZZ0010)

中文摘要:目的:对江香薷的较大极性部分的化学成分进行分离鉴定。方法:运用柱色谱和高效液相进行分离纯化,通过理化性质和波谱分析鉴定结构。结果:从中分离得到了7个苷类化合物,分别鉴定为4-羟基-2,6-二甲氧基苯基- β -D-吡喃葡萄糖苷(1),4-羟基-3,5-二甲氧基苯基- β -D-吡喃葡萄糖苷(2),3,4,5-三甲氧基苯基- β -D-吡喃葡萄糖苷(3),3-羟基雌二醇- β -D-吡喃葡萄糖苷(4),(6S,9R)-长寿花糖苷(5),腺苷(6),和对羟基苯甲酸- β -D-吡喃葡萄糖苷(7)。结论:化合物1-7均为首次从该属植物中分离得到。

中文关键词:江香薷 石蕊苣苔属 极性成分

Polar constituents of *Mosla chinensis*

Abstract:Objective: To study polar constituents of *Mosla chinensis*. Method: The constituents were isolated and purified by various chromatographic techniques and their structures were elucidated by physico-chemical properties and spectroscopic data. Result: Seven glucosides were obtained and their structures were identified as 4-hydroxy-2,6-dimethoxyphenyl- β -D-glucopyranoside (1), 4-hydroxy-3,5-dimethoxyphenyl- β -D-glucopyranoside (2), 3,4,5-trimethoxyphenyl- β -D-glucopyranoside (3), 3-hydroxyestradiol- β -D-glucopyranoside (4), (6S,9R)-rososide (5), adenosine (6), and p-hydroxybenzoic acid glucoside (7). Conclusion: All compounds were isolated from the genus *Mosla* for the first time.

keywords: *Mosla chinensis* *Mosla* polar constituents

[查看全文](#) [查看/发表评论](#) [下载PDF阅读器](#)